The EY organization has announced the acquisition of Aqurance A.E. (Aqurance), a Veeva services partner located in Greece. Aqurance is well-respected in the industry for its ability to deliver integrated clinical, commercial, and digital transformation programs specifically designed for life sciences companies across the globe.
This acquisition is a strategic move that enhances EY’s value proposition. By combining EY’s extensive knowledge of regulatory requirements with Aqurance’s specialized expertise in Veeva Vault and related applications, the organization is well-equipped to offer a broader range of services.
EY’s capabilities in business design, change management, program management, technology integration, deployment, and business operations mesh effectively with Aqurance’s strengths, promising to improve efficiency and compliance in the life sciences sector.
Aqurance has earned the distinction of being a Premier Services Partner for Veeva Commercial Cloud and a Services Partner for Veeva Development Cloud. This recognition showcases Aqurance’s significant experience and knowledge, particularly beneficial for customers seeking consulting services across Veeva applications in both Commercial and Research and Development (R&D).
The integration of Aqurance’s team into EY is expected to substantially enhance the organization’s ability to support clients transitioning to Vault CRM while also fostering innovations in Customer Relationship Management (CRM), regulatory transformation, and overall platform integration.
Additionally, the acquisition strengthens EY’s Veeva Centers of Excellence. These centers play a pivotal role in helping clients adopt and scale a unified platform that enhances customer engagement, regulatory compliance, and clinical trial execution.
With the combined expertise of EY and Aqurance, life sciences organizations will be better equipped to harness artificial intelligence (AI) and optimize their enterprise data across various segments of their value chains.
Moreover, this acquisition positions the EY organization to deliver a comprehensive and integrated client migration capability. As life sciences organizations navigate the ever-changing market landscape and regulatory requirements, they will benefit from the support offered by EY. This is increasingly important as businesses seek to adapt to the growing demand for interconnected digital platforms.
As part of its initiatives following the acquisition, EY Aqurance will serve as a platinum sponsor at the upcoming Veeva Commercial Summit, taking place in Madrid on November 5-6, 2025.
KEY QUOTES:
“This is a pivotal moment for the industry as life sciences companies make critical decisions about platform migration, compliance and data integration. With the acquisition of Aqurance, the EY organization can offer clients a more integrated pathway — strategy through execution — to unlock the full power of Veeva technology. Together, we will help companies move faster, stay compliant and use data and AI to help drive more informed decisions across the enterprise.”
Dan Mathews, EY Global Life Sciences Leader
“When we considered our next chapter, we had many options, but the EY organization stood out. The EY organization brings the scale, global reach and credibility that allows our knowledge to make a far greater impact. By combining Aqurance’s deep Veeva knowledge with the EY organization’s transformation capabilities, we can help clients achieve outcomes they cannot provide alone — from seamless migrations to enterprise-wide digital change that should truly help move the needle for the life sciences industry.”
Dionissis Nikolopoulos, Founder & CEO at Aqurance
